<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0, user-scalable=no" />
        <title>Full STD Guidelines</title>

        <link href="../jquery-mobile/jquery.mobile.theme-1.2.0.min.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.f.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.j.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.structure-1.2.0.min.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/full.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/recreated_tables.css" rel="stylesheet" type="text/css"/>
        <script src="../jquery-mobile/jquery-1.8.2.min.js" type="text/javascript"></script>
        <script src="../jquery-customization.js" type="text/javascript"></script>
        <script src="../jquery-mobile/jquery.mobile-1.2.0.min.js" type="text/javascript"></script>
        <script src="../cordova-2.2.0.js" type="text/javascript" charset="utf-8"></script>
        <script src="../assets/js/metrics.js" type="text/javascript" charset="utf-8"></script>

    </head>
    <body>

        <!-- Start of page -->
        <div data-role="page" id="heading_page_410" data-theme="d">
            <div data-role="header" data-id="guidelines-header" data-theme="j" data-position="fixed">
                <a href="lv-409.html" data-role="button" data-iconshadow="false" data-corners="false" data-theme="reset" data-transition="fade" class="back_button" role="button" aria-label="back"></a>
                <h1>Full STD Guidelines</h1>
	            <a href="../menu.html"  rel="external" data-role="button" data-theme="reset" data-transition="fade" data-iconshadow="false" data-corners="false" class="menu_button ui-btn-right" role="button" aria-label="main menu"></a>
            </div>  <!-- end of header div -->

            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-0.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-409.html" >References</a><span class="carrot"> > </span>References 1-50
            </div>   <!-- end of guidelines listview breadcrumbs -->
            </br><h2 id="sigil_toc_id_410">
 References 1-50
</h2>
<p>
 1. CDC. Sexually transmitted diseases treatment guidelines, 2006. MMWR 2006;55(No. RR-11).
</p>
<p>
 2. CDC. Prevention of hepatitis A through active or passive immunization:&nbsp;recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-7).
</p>
<p>
 3. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR 2006;55(No. RR-16).
</p>
<p>
 4. CDC. A comprehensive immunization strategy to eliminate transmission&nbsp;of hepatitis B virus infection in the United States: recommendations&nbsp;of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. MMWR 2005;54(No. RR-16).
</p>
<p>
 5. Lin JS, Whitlock E, O&lsquo;Connor E, et al. Behavioral counseling to prevent&nbsp;sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:497&ndash;9.
</p>
<p>
 6. U.S. Preventive Services Task Force. Behavioral counseling to prevent sexually transmitted infections: recommendation statement. Ann Intern Med 2008;149:491&ndash;6.
</p>
<p>
 7. Hatcher RA, Trussell J, Nelson AL, et al. Contraceptive technology. 19th ed. New York: Ardent Media; 2007.
</p>
<p>
 8. Kamb ML, Fishbein M, Douglas JM, Jr., et al. Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA 1998;280:1161&ndash;7.
</p>
<p>
 9. Gottlieb SL, Douglas JM, Jr., Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 2004;190:1059&ndash;67.
</p>
<p>
 10. Warner L, Klausner JD, Rietmeijer CA, et al. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med 2008;5:e135.
</p>
<p>
 11. CDC, Health Resources and Services Administration, National Institutes of Health, NIV Medicine Association of the Infectious Diseases Society of American, HIV Prevention in Clinical Care Working Group. Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV. Clin Infect Dis 2004;38:104&ndash;21.
</p>
<p>
 12. Wingood GM, DiClemente RJ, Mikhail I, et al. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted&nbsp;diseases among women living with HIV: The WiLLOW Program. J Acquir Immune Defic Syndr 2004;37(Suppl 2):S58&ndash;67.
</p>
<p>
 13. Richardson JL, Milam J, Stoyanoff S, et al. Using patient risk indicators to plan prevention strategies in the clinical care setting. J Acquir Immune Defic Syndr 2004;37(Suppl 2):S88&ndash;94.
</p>
<p>
 14. Fisher JD, Cornman DH, Osborn CY, et al. Clinician-initiated HIV risk reduction intervention for HIV-positive persons: Formative Research, Acceptability, and Fidelity of the Options Project. J Acquir Immune Defic Syndr 2004;37(Suppl 2):S78&ndash;87.
</p>
<p>
 15. CDC. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-2).
</p>
<p>
 16. CDC. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations&nbsp;from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:626&ndash;9.
</p>
<p>
 17. CDC. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:630&ndash;2.
</p>
<p>
 18. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;(1):CD003255.
</p>
<p>
 19. Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004;94:1327&ndash;9.
</p>
<p>
 20. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing&nbsp;sexually transmitted infections. Bull World Health Organ 2004;82:454&ndash;61.
</p>
<p>
 21. Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005;143:707&ndash;13.
</p>
<p>
 22. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009;169:1233&ndash;40.
</p>
<p>
 23. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100&ndash;6.
</p>
<p>
 24. Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis 2009;36:401&ndash;5.
</p>
<p>
 25. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital&nbsp;human papillomavirus infection in young women. N Engl J Med 2006;354:2645&ndash;54.
</p>
<p>
 26. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003;107:811&ndash;6.
</p>
<p>
 27. Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003;107:804&ndash;10.
</p>
<p>
 28. Steiner MJ, Cates W Jr, Warner L. The real problem with male condoms is nonuse. Sex Transm Dis 1999;26:459&ndash;62.
</p>
<p>
 29. NIAID. Workshop summary: scientific evidence on condom effectiveness for sexually transmitted disease (STD) prevention. 2001. Available at
 <a href="http://www.niaid.nih.gov/about/organization/dmid/documents/condomreport.pdf">
  www.niaid.nih.gov/about/organization/dmid/documents/condomreport.pdf
 </a>
 .
</p>
<p>
 30. Gallo MF, Grimes DA, Lopez LM, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev 2006;1:CD003550.
</p>
<p>
 31. Macaluso M, Blackwell R, Jamieson DJ, et al. Efficacy of the male latex condom and of the female polyurethane condom as barriers to semen during intercourse: a randomized clinical trial. Am J Epidemiol 2007;166:88&ndash;96.
</p>
<p>
 32. French PP, Latka M, Gollub EL, et al. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis 2003;30:433&ndash;9.
</p>
<p>
 33. Gross M, Buchbinder SP, Holte S, et al. Use of reality &ldquo;female condoms&rdquo; for anal sex by US men who have sex with men. HIVNET Vaccine Preparedness Study Protocol Team. Am J Public Health 1999;89:1739&ndash;41.
</p>
<p>
 34. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect 2005;81:193&ndash;200.
</p>
<p>
 35. Padian NS, van der SA, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007;370:251&ndash;61.
</p>
<p>
 36. Ramjee G, van der SA, Chipato T, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One 2008;3:e3488.
</p>
<p>
 37. Fihn SD, Boyko EJ, Normand EH, et al. Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women. Am J Epidemiol 1996;144:512&ndash;20.
</p>
<p>
 38. Padian NS, Buve A, Balkus J, et al. Biomedical interventions to prevent&nbsp;HIV infection: evidence, challenges, and way forward. Lancet 2008;372:585&ndash;99.
</p>
<p>
 39. Cates W, Feldblum P. HIV prevention research: the ecstasy and the agony. Lancet 2008;372:1932&ndash;3.
</p>
<p>
 40. Wilkinson D, Tholandi M, Ramjee G, et al. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted&nbsp;infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002;2:613&ndash;7.
</p>
<p>
 41. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977&ndash;87.
</p>
<p>
 42. Van DL, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463&ndash;72.
</p>
<p>
 43. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474.
</p>
<p>
 44. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention&nbsp;of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007;2:e1312.
</p>
<p>
 45. Karim SA, Coletti A, Richardson BS. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. In: 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
</p>
<p>
 46. Microbicides Development Programme. Technical fact sheet for scientists (MDP 301). London, 2009. Available at http://www.mdp.mrc.ac.uk.
</p>
<p>
 47. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168&ndash;74.
</p>
<p>
 48. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention&nbsp;in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643&ndash;6.
</p>
<p>
 49. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657&ndash;66.
</p>
<p>
 50. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention&nbsp;trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298.
</p>

            </div>
            <script type="text/javascript">

                $('div').live('pageshow', function (event, ui) {
                    document.addEventListener("deviceready", function(){
                        trackFullGuidelinesPageView("410");
                                                },true);
                });
            </script>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

    